BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

SETDB1 regulates SMAD7 expression for breast cancer metastasis

  • Ryu, Tae Young (Korea Research Institute of Bioscience and Biotechnology) ;
  • Kim, Kwangho (Korea Research Institute of Bioscience and Biotechnology) ;
  • Kim, Seon-Kyu (Korea Research Institute of Bioscience and Biotechnology) ;
  • Oh, Jung-Hwa (Korea Institute of Toxicology (KIT)) ;
  • Min, Jeong-Ki (Korea Research Institute of Bioscience and Biotechnology) ;
  • Jung, Cho-Rok (Korea Research Institute of Bioscience and Biotechnology) ;
  • Son, Mi-Young (Korea Research Institute of Bioscience and Biotechnology) ;
  • Kim, Dae-Soo (Korea Research Institute of Bioscience and Biotechnology) ;
  • Cho, Hyun-Soo (Korea Research Institute of Bioscience and Biotechnology)
  • Received : 2018.10.05
  • Accepted : 2018.12.03
  • Published : 2019.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Breast cancer (BRC) is the most invasive cancer in women. Although the survival rate of BRC is gradually increasing due to improved screening systems, development of novel therapeutic targets for inhibition of BRC proliferation, metastasis and recurrence have been constantly needed. Thus, in this study, we identified overexpression of SETDB1 (SET Domain Bifurcated 1), a histone methyltransferase, in RNA-seq data of BRC derived from TCGA portal. In Gene Ontology (GO) analysis, cell migration-related GO terms were enriched, and we confirmed down-regulation of cell migration/invasion and alteration of EMT /MET markers after knockdown of SETDB1. Moreover, gene network analysis showed that SMAD7 expression is regulated by SETDB1 levels, indicating that up-regulation of SMAD7 by SETDB1 knockdown inhibited BRC metastasis. Therefore, development of SETDB1 inhibitors and functional studies may help develop more effective clinical guidelines for BRC treatment.

Keywords

References

  1. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13, 4429-4434 https://doi.org/10.1158/1078-0432.CCR-06-3045
  2. Lee A and Djamgoz MBA (2017) Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev 62, 110-122 https://doi.org/10.1016/j.ctrv.2017.11.003
  3. Park J, Jang JH, Park GS, Chung Y, You HJ and Kim JH (2018) BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer. BMB Rep 51, 373-377 https://doi.org/10.5483/BMBRep.2018.51.8.127
  4. Kim K, Son MY, Jung CR, Kim DS and Cho HS (2018) EHMT2 is a metastasis regulator in breast cancer. Biochem Biophys Res Commun 496, 758-762 https://doi.org/10.1016/j.bbrc.2018.01.074
  5. Song H, Li D, Wu T et al (2018) MicroRNA-301b promotes cell proliferation and apoptosis resistance in triple-negative breast cancer by targeting CYLD. BMB Rep 51, 602-607 https://doi.org/10.5483/BMBRep.2018.51.11.168
  6. Schultz DC, Ayyanathan K, Negorev D, Maul GG and Rauscher FJ 3rd (2002) SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev 16, 919-932 https://doi.org/10.1101/gad.973302
  7. Kazanets A, Shorstova T, Hilmi K, Marques M and Witcher M (2016) Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential. Biochim Biophys Acta 1865, 275-288
  8. Kondo Y, Shen L and Issa JP (2003) Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 23, 206-215 https://doi.org/10.1128/MCB.23.1.206-215.2003
  9. Han TS, Ban HS, Hur K and Cho HS (2018) The epigenetic regulation of HCC metastasis. Int J Mol Sci 19, 3978 https://doi.org/10.3390/ijms19123978
  10. Ceol CJ, Houvras Y, Jane-Valbuena J et al (2011) The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471, 513-517 https://doi.org/10.1038/nature09806
  11. Chen K, Zhang F, Ding J et al (2017) Histone Methyltransferase SETDB1 promotes the progression of colorectal cancer by inhibiting the expression of TP53. J Cancer 8, 3318-3330 https://doi.org/10.7150/jca.20482
  12. Ho YJ, Lin YM, Huang YC et al (2017) Significance of histone methyltransferase SETDB1 expression in colon adenocarcinoma. APMIS 125, 985-995 https://doi.org/10.1111/apm.12745
  13. Spyropoulou A, Gargalionis A, Dalagiorgou G et al (2014) Role of histone lysine methyltransferases SUV39H1 and SETDB1 in gliomagenesis: modulation of cell proliferation, migration, and colony formation. Neuromolecular Med 16, 70-82 https://doi.org/10.1007/s12017-013-8254-x
  14. Wong CM, Wei L, Law CT et al (2016) Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis. Hepatology 63, 474-487 https://doi.org/10.1002/hep.28304
  15. Zhang H, Cai K, Wang J et al (2014) MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway. Stem Cells 32, 2858-2868 https://doi.org/10.1002/stem.1795
  16. Eymery A, Liu Z, Ozonov EA, Stadler MB and Peters AH (2016) The methyltransferase Setdb1 is essential for meiosis and mitosis in mouse oocytes and early embryos. Development 143, 2767-2779 https://doi.org/10.1242/dev.132746
  17. Na HH and Kim KC (2018) SETDB1-mediated FosB regulation via ERK2 is associated with an increase in cell invasiveness during anticancer drug treatment of A549 human lung cancer cells. Biochem Biophys Res Commun 495, 512-518 https://doi.org/10.1016/j.bbrc.2017.10.176
  18. Zhang Y, Huang J, Li Q et al (2018) Histone methyltransferase SETDB1 promotes cells proliferation and migration by interacting withTiam1 in hepatocellular carcinoma. BMC Cancer 18, 539 https://doi.org/10.1186/s12885-018-4464-9
  19. Miyazawa K and Miyazono K (2017) Regulation of TGF-beta family signaling by inhibitory smads. Cold Spring Harb Perspect Biol 9
  20. Chen X, Wang Z, Ma H et al (2017) Melatonin attenuates hypoxia-induced epithelial-mesenchymal transition and cell aggressive via Smad7/ CCL20 in glioma. Oncotarget 8, 93580-93592 https://doi.org/10.18632/oncotarget.20525
  21. Juarez P, Fournier PGJ, Mohammad KS et al (2017) Halofuginone inhibits TGF-beta/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis. Oncotarget 8, 86447-86462 https://doi.org/10.18632/oncotarget.21200
  22. Wang H, Nie L, Wu L, Liu Q and Guo X (2017) NR2F2 inhibits Smad7 expression and promotes TGF-beta- dependent epithelial-mesenchymal transition of CRC via transactivation of miR-21. Biochem Biophys Res Commun 485, 181-188 https://doi.org/10.1016/j.bbrc.2017.02.049
  23. Zhang Z, Fan Y, Xie F et al (2017) Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7. Nat Commun 8, 2116 https://doi.org/10.1038/s41467-017-02029-7
  24. Sauter ER (2018) Breast cancer prevention: current approaches and future directions. Eur J Breast Health 14, 64-71
  25. Ross JS and Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16, 413-428 https://doi.org/10.1002/stem.160413
  26. Regina C, Compagnone M, Peschiaroli A et al (2016) Setdb1, a novel interactor of DeltaNp63, is involved in breast tumorigenesis. Oncotarget 7, 28836-28848 https://doi.org/10.18632/oncotarget.7089
  27. Comsa S, Cimpean AM and Raica M (2015) The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. Anticancer Res 35, 3147-3154
  28. Gest C, Joimel U, Huang L et al (2013) Rac3 induces a molecular pathway triggering breast cancer cell aggressiveness: differences in MDA-MB-231 and MCF-7 breast cancer cell lines. BMC Cancer 13, 63 https://doi.org/10.1186/1471-2407-13-63
  29. Bellomo C, Caja L and Moustakas A (2016) Transforming growth factor beta as regulator of cancer stemness and metastasis. Br J Cancer 115, 761-769 https://doi.org/10.1038/bjc.2016.255
  30. Kim SK, Kim K, Ryu JW et al (2019) The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer. Int J Oncol 54, 65-76 https://doi.org/10.3892/ijo.2018.4608
  31. Ryu JW, Kim SK, Son MY et al (2017) Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC. Oncotarget 8, 115444-115455 https://doi.org/10.18632/oncotarget.23296
  32. Jung KB, Lee H, Son YS et al (2018) In vitro and in vivo imaging and tracking of intestinal organoids from human induced pluripotent stem cells. FASEB J 32, 111-122 https://doi.org/10.1096/fj.201700504R
  33. Kim DS, Ryu JW, Son MY et al (2017) A liver-specific gene expression panel predicts the differentiation status of in vitro hepatocyte models. Hepatology 66, 1662-1674 https://doi.org/10.1002/hep.29324
  34. Son MY, Jung CR, Kim DS and Cho HS (2018) Comparative in silico profiling of epigenetic modifiers in human tissues. Mol Biol Rep 45, 309-314 https://doi.org/10.1007/s11033-018-4163-2